NASDAQ · NOVT
Technology · Hardware, Equipment & Parts
$138.23
Down-$5.43 (-3.93%)
Updated Sep 17, 2026, 12:28 AM
SID Score
4.0/10
Composite research score
Smart Money
62/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
NOVT closed at $138.23 after 19 trading sessions, down 5.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $141.40 | $141.40 | $137.81 | $138.23 | 401.38K |
| Sep 14, 2026 | $142.63 | $142.80 | $139.11 | $140.05 | 340.53K |
| Sep 11, 2026 | $146.41 | $149.00 | $146.075 | $146.56 | 257.25K |
| Sep 10, 2026 | $143.72 | $146.125 | $142.476 | $143.91 | 183.32K |
| Sep 9, 2026 | $148.02 | $150.88 | $145.55 | $145.76 | 291.24K |
| Sep 8, 2026 | $148.36 | $153.155 | $147.98 | $149.31 | 304.98K |
| Sep 4, 2026 | $147.23 | $149.88 | $147.095 | $148.36 | 218.13K |
| Sep 3, 2026 | $144.74 | $147.71 | $142.145 | $147.24 | 270.07K |
| Sep 2, 2026 | $144.98 | $147.13 | $142.68 | $144.52 | 255.51K |
| Sep 1, 2026 | $144.19 | $145.23 | $141.57 | $143.67 | 363.6K |
| Aug 31, 2026 | $142.20 | $146.77 | $141.54 | $146.22 | 385.84K |
| Aug 28, 2026 | $145.78 | $146.31 | $140.97 | $142.20 | 265.47K |
| Aug 27, 2026 | $144.56 | $147.31 | $142.96 | $144.65 | 278.14K |
| Aug 26, 2026 | $139.65 | $145.72 | $139.22 | $143.96 | 311.53K |
| Aug 25, 2026 | $141.88 | $142.53 | $139.16 | $139.65 | 307.91K |
| Aug 24, 2026 | $143.86 | $143.86 | $138.435 | $139.48 | 438.45K |
| Aug 21, 2026 | $146.85 | $150.01 | $143.855 | $145.24 | 332.43K |
| Aug 20, 2026 | $143.55 | $148.18 | $143.43 | $145.52 | 439.65K |
| Aug 19, 2026 | $159.71 | $159.71 | $145.77 | $145.94 | 456.19K |
The latest Smart Investors Daily articles mentioning NOVT.
NOVT research
Company profile and research snapshot.
Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 13, 2026 | Baird | Outperform | — |
| Mar 30, 2026 | Baird | Outperform | — |
| Aug 11, 2025 | Baird | Neutral | — |
| Mar 3, 2025 | Baird | Neutral | — |
| Nov 6, 2024 | Baird | Neutral | — |
No generated briefing is available yet.
ChartMill · Sep 10, 2026
Novanta (NOVT) passes key quality tests—strong EBIT growth, 22.9% core ROIC, low debt—but valuation and margin trends warrant caution.
Benzinga · Sep 7, 2026
Novanta (NASDAQ:NOVT) has outperformed the market over the past 15 years by 7.74% on an annualized basis producing an average annual return of 21.09%. Currently, Novanta has a market capitalization of $5.28 billion.
SeekingAlpha · Aug 23, 2026
Novanta completed the Riverpoint Medical acquisition, enhancing recurring consumables and medical business growth prospects.
Benzinga · Aug 21, 2026
Novanta (NASDAQ:NOVT) has outperformed the market over the past 10 years by 10.52% on an annualized basis producing an average annual return of 23.93%. Currently, Novanta has a market capitalization of $5.17 billion.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NOVT.
